Alterations in the apoptotic machinery and their potential role in anticancer drug resistance.
about
TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cellsProapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.Serine protease HtrA1 modulates chemotherapy-induced cytotoxicityResponse rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathwaysApoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic HyperplasiaCaenorhabditis elegans as a model for cancer researchLabel-free recognition of drug resistance via impedimetric screening of breast cancer cellsHydrophobicity of Antifungal β-Peptides Is Associated with Their Cytotoxic Effect on In Vitro Human Colon Caco-2 and Liver HepG2 CellsCyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancerInteraction of translationally controlled tumor protein with Apaf-1 is involved in the development of chemoresistance in HeLa cellsIdentification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.Snake venom toxin from Vipera lebetina turanica induces apoptosis of colon cancer cells via upregulation of ROS- and JNK-mediated death receptor expressionSRT1720 induces lysosomal-dependent cell death of breast cancer cells.Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimineDevelopment of laser ionization techniques for evaluation of the effect of cancer drugs using imaging mass spectrometryEffects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.High cell surface death receptor expression determines type I versus type II signalingA whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer modelsThe molecular mechanisms of glucocorticoids-mediated neutrophil survival.The DAXX co-repressor is directly recruited to active regulatory elements genome-wide to regulate autophagy programs in a model of human prostate cancer.Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomyUsing microarrays to predict resistance to chemotherapy in cancer patients.PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer.The protein structures that shape caspase activity, specificity, activation and inhibition.Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.BP1 transcriptionally activates bcl-2 and inhibits TNFalpha-induced cell death in MCF7 breast cancer cellsThe AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cellsThe apoptosome: emerging insights and new potential targets for drug designOverexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1.Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death.Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis.Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach.Toxicogenomics of A375 human malignant melanoma cells.Big wheel keeps on turning: apoptosome regulation and its role in chemoresistance.Clinical potential of targeting Bruton's tyrosine kinase.To kill a tumor cell: the potential of proapoptotic receptor agonistsCatalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers
P2860
Q21260428-9E0A92B6-12DC-4212-A874-AE35528F83AEQ24302494-461EE77B-B36C-459A-B7E9-0AD64CA9FD1EQ24547477-C693302A-140A-47E2-9F2A-C2D12DB5EB9DQ24810525-412FFC0A-EAF2-4020-9489-F1A29FB96251Q26741226-B6515819-AC38-466C-9811-445BF6AA66D2Q26828013-31D5D7FB-23F5-43CD-9967-CC155B7F0E28Q28487553-30E1F7DF-B21F-478D-BC3C-EC06762F119DQ28550897-BC0360BB-0BCF-4C9C-B598-43DFC283C0D7Q29248648-21C77385-BF3A-475D-9593-6B2D82E61977Q33587295-CC28B4B7-5FA2-4BB8-B11D-B99F69B7FE86Q34219368-EC3CA361-397E-44EE-ACE7-2C2FA90CF2D7Q34297762-DC9CFE4E-7660-42A9-935B-7F5426DD4805Q34978389-BD86A98D-95E0-45C0-AD49-AB6FF3A59B89Q35080206-CB63029D-A1FE-4490-96E3-4B673F1008F5Q35195744-16AEAE5C-14FF-4F70-ACE3-C2341F06CF1FQ35287729-BF4C5A8F-F2A4-40B6-AA7B-45B62989655EQ35371553-2F7CB94F-09B1-466E-BDEE-4960FD2F1E85Q35470360-D3D66340-6AC7-4367-A06D-59244705EBE8Q35579598-7B0CD23F-7CE0-4EBF-B33F-BF17B0730628Q35587389-73C0C7C8-D828-4CD7-B4EA-961E09732AF9Q35701310-812D71CD-BA5D-4BE0-9420-22808559F1CCQ35744998-C59222D1-B0C5-4EC4-B889-96DC263E5733Q35751889-730FBB14-6E54-4E7D-BBB9-8EAB1BAEEB1EQ35873673-D148DD0F-BF36-4182-8471-B5D0759B3B20Q35886689-BA082CF8-AFEF-48EE-88DF-0EEE4416A9B4Q35902423-F96A721D-F267-4109-93C2-D771E033E8BFQ36360770-46C591C9-DC83-40A7-8CA5-B5DC9AF317D1Q36458739-35C068AB-6A6A-4254-BED1-4FE939B19F83Q36502377-C8EDA24A-209B-4BED-8562-5341A4A061C7Q36517696-25122589-7A0F-437C-8EF6-0DD0CD571B19Q36540852-8D10F39D-5AE8-461A-942D-7E0A442AA5DAQ36586495-18308E13-506F-407F-B9F3-D5B0D4391FC8Q36611534-780C77A3-B0C6-45F8-BBE1-C81F8C2C7A9CQ36849135-573F2C43-D156-4FCE-8278-0D7A0ADAFC5CQ36907121-2357B191-CAFB-4468-BD02-C402350F5173Q36918133-0FED0731-B04C-49FB-9EAC-76906928CAA5Q36988138-6E0975DE-4246-47D0-8EAE-B46AC3A4821AQ37094690-925BCE47-9E44-42E6-93FF-F2D600F0D81AQ37181734-1C9FEE04-5B2E-4770-BF71-842ECB4A449DQ37254021-1E58C99E-D07C-448C-8416-C56513DF6E1E
P2860
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Alterations in the apoptotic m ...... in anticancer drug resistance.
@ast
Alterations in the apoptotic m ...... in anticancer drug resistance.
@en
type
label
Alterations in the apoptotic m ...... in anticancer drug resistance.
@ast
Alterations in the apoptotic m ...... in anticancer drug resistance.
@en
prefLabel
Alterations in the apoptotic m ...... in anticancer drug resistance.
@ast
Alterations in the apoptotic m ...... in anticancer drug resistance.
@en
P356
P1433
P1476
Alterations in the apoptotic m ...... in anticancer drug resistance.
@en
P2888
P304
P356
10.1038/SJ.ONC.1206945
P407
P577
2003-10-01T00:00:00Z
P5875
P6179
1053167469